Drug Price Transparency in Medicaid Act of 2019

House Bill 5281 - Drug Price Transparency in Medicaid Act of 2019: Overview, Status, and Impact

Hozzl · 2022-10-28T01:46:07Z

Explore the details of House Bill 5281 Drug Price Transparency in Medicaid Act of 2019 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:46 AM

Congressional Summary of HR 5281

Drug Price Transparency in Medicaid Act of 2019

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5281

Bill HR 5281 is currently in the status of Bill Introduced since December 3, 2019. Bill HR 5281 was introduced during Congress 116 and was introduced to the House on December 3, 2019. Bill HR 5281's most recent activity was Referred to the Subcommittee on Health. as of December 4, 2019

Bipartisan Support of Bill HR 5281

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5281

Primary Policy Focus

Health

Potential Impact Areas

- Business records

- Congressional oversight

- Government information and archives

- Health care costs and insurance

- Home and outpatient care

- Inflation and prices

- Medicaid

- Prescription drugs

- Public contracts and procurement

- Retail and wholesale trades

- State and local government operations

- User charges and fees

Alternate Title(s) of Bill HR 5281

Drug Price Transparency in Medicaid Act of 2019

To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program.

Drug Price Transparency in Medicaid Act of 2019